LOLouis Onghena

Louis Onghena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Louis Onghena has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Experiences of LGB patients undergoing colorectal cancer surgery: A focus on sexuality

    by Anna Provoost, Louis Onghena, Khushi Jeswani, Yves van Nieuwenhove, Eva Pape, Gabrielle H. van Ramshorst

    Purpose: This study aimed to delineate the existing knowledge regarding the impact of colorectal cancer surgery on the sexuality of LGB patients, highlighting the need for culturally competent care tailored to their unique needs. Methods: A comprehensive search was conducted from October 2024 onwards across PubMed, Embase, CINAHL, Google Scholar, Web of Science, Scopus, PsychINFO, Cochrane Library, and Joanna Briggs Institute using the MeSH terms ‘sexual and gender minorities’, ‘colorectal surgery’, ‘colorectal neoplasms’ and ‘sexuality’. Inclusion criteria required LGB patients over 18 years, at least 50% of the sample diagnosed with colorectal cancer and treated operatively. All studies were critically appraised. Results: Six studies from the UK and the US were included. Sample size ranged from 1 to 480. Participants identifying as LGB ranged from 26.4 to 100%. Key findings revealed LGB patients experience similar physical consequences to heterosexual patients (erectile and ejaculatory dysfunction, dyspareunia, vaginal dryness), but implications might differ, e.g., regarding anal intercourse. A lower mental quality of life was reported, including body image issues related to stomas. Relationship challenges and intimacy issues were highlighted. The cultural competence of healthcare providers has a significant influence on patient experiences, highlighting a gap in inclusive care. Critical appraisal revealed both methodological strengths and weaknesses. Conclusion: This review highlighted the sexual health challenges of LGB patients after colorectal cancer surgery, with issues like sexual function and mental wellbeing often being underreported. Cultural competence training for healthcare providers and integrating patients' partners into cancer care are crucial for a holistic approach.

  • Open Access

    The double-edged sword of metabolic and bariatric surgery: extending the biliary limb can trigger bacterial translocation, sepsis, and liver inflammation – an experimental study

    by Louis Onghena, Anneleen Dvm Heldens, Kim De Paepe, Milton Antwi, Hans Van Vlierberghe, Sarah Raevens, Xavier Verhelst, Anne Hoorens, Lindsey Dvm Devisscher, Yves van Nieuwenhove, et al.

    Background: Metabolic and bariatric surgery (MBS) procedures with extended biliary limb length are gaining popularity to expedite weight loss but can induce liver failure. We aimed to investigate the underlying pathophysiology for this potentially fatal complication. Materials and Methods: We compared mouse models of vertical sleeve plication, sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), and one-anastomosis gastric bypass with three biliary limb lengths (25% = Ω1, 50% = Ω2, 75% = Ω3) by analyzing mortality, weight loss, metabolic and liver health, bacterial translocation, inflammation, and biliary and fecal microbiome. Gut decontamination with oral antibiotics (amoxicillin, vancomycin, neomycin, and metronidazole) was performed in a subset of Ω3 mice. Liver histology from mice with different biliary limb lengths was compared to samples from human patients who developed liver failure following biliopancreatic diversion or RYGB. Results: RYGB and Ω1&2 significantly improved glucose intolerance and liver steatosis compared to sham surgery. However, extending the biliary limb (Ω3) resulted in 100% mortality. The Ω3 procedure induced bacterial translocation of Enterococcus genus to the spleen and biliary fluid, consistent with increased serum lipopolysaccharide levels and terminal ileum, biliary limb, and hepatic inflammation. Liver histology in Ω3 mice was characterized by mediovesicular steatosis, closely resembling the histological picture observed in patients with liver failure after MBS. Oral gut decontamination significantly improved Ω3 1-week-survival from 31.3% to 80.0%, prevented bacterial overgrowth in biliary fluid and spleen, and decreased liver damage. Conclusion: Mortality in longer biliary limb MBS surgery is caused by bacterial overgrowth, translocation, and gut–liver axis inflammation, which were reversed by oral gut decontamination with antibiotics.


  • Open Access

    Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD

    by Anneleen Heldens, Milton Antwi, Louis Onghena, Tim Meese, Yannick Gansemans, Joél Smet, Ellen Dupont, Xavier Verhelst, Sarah Raevens, Hans Van Vlierberghe, et al.


  • Open Access

    Prior metabolic and bariatric surgery is an independent determinant of severity of decompensation in alcohol‐associated liver disease

    by Louis Onghena, Yves van Nieuwenhove, Hans Van Vlierberghe, Lindsey Devisscher, Sarah Raevens, Xavier Verhelst, Sander Lefere, Anja Geerts

    Background: Patients with a history of metabolic and bariatric surgery (MBS) are susceptible to developing alcohol use disorder, potentially resulting in end‐stage liver disease, with a paucity of data on the evolution of cirrhosis. Aims: Our aim was to describe the demographics and mortality in hospitalizations over time in individuals diagnosed with cirrhosis due to alcohol‐associated liver disease (ALD) in relation to prior MBS. Methods: We included patients hospitalized at the Ghent University Hospital between 1/1/2010 and 01/09/2023 with cirrhosis due to ALD. Data were retrieved retrospectively from all hospitalizations. Results: 46/275 (16.7%) of individuals with cirrhosis admitted with ALD had a history of MBS; they were predominantly female (76.1%), in contrast to the non‐MBS population (29.7%) ( p < 0.0001) and were significantly younger at the time of diagnosis (46 vs. 58 years, p < 0.0001). Liver disease evolved at a faster pace in the MBS group with a shorter time to first hospitalization (5 vs. 13 months, p = 0.036), and consecutive hospitalizations. The proportion with primary hospitalization due to acute‐on‐chronic liver failure (ACLF) was significantly larger in the MBS group (60.9% vs. 27.6%, p < 0.0001), and throughout the following hospitalizations, ACLF remained more prevalent in the MBS group. Modeled transplant‐free survival was lower in the MBS group ( p = 0.004), with ACLF as the main cause of death. The weekly amount of alcohol consumed during drinking periods and duration of use were significantly lower in the MBS group. Conclusions: MBS patients hospitalized with ALD develop acute decompensation at a faster pace, with more overall ACLF hospitalizations, and higher cumulative mortality, despite being 12 years younger on average. Clinical trial registration: Not applicable.


  • Open Access

    PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression

    by Milton Boaheng Antwi, Sander Lefere, Dorien Clarisse, Lisa Koorneef, Anneleen Heldens, Louis Onghena, Kylian Decroix, Daria Fijalkowska, Jonathan Thommis, Madeleine Hellemans, et al.

    Background and aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common liver disease worldwide. This study investigates how targeting two key nuclear receptors involved in hepatic energy metabolism, peroxisome proliferator-activated receptor alpha (PPARα) and estrogen-related receptor alpha (ERRα), impacts MASLD. Methods The PPARα agonist pemafibrate and/or ERRα inverse agonist C29 were administered in a short- and long-term Western diet plus fructose model, and a diabetic-background streptozotocin-Western diet model (STZ-WD). Liver morphology, histological samples, serum metabolites, RNA and protein levels were analysed and scanning electron microscopy was performed. In addition, we performed cell-based assays and immunohistochemistry and immunofluorescence stainings with light and super-resolution confocal microscopy of healthy, MASLD and MASH human livers. Results The ligand combinations’ efficacy was underscored by reduced liver steatosis in all the mouse models. Both long-term models showed improvements in body weight and liver morphology, alongside reductions in inflammation and fibrosis. Additionally, tumor formation was prevented in the STZ-WD mice model. Cell-based assays demonstrated that ERRα inhibits PPARα’s activity, likely explaining why ERRα blockage improves inflammatory and lipid metabolism gene profiles and enhances lipid-lowering effects. Complementary RNA sequencing and shotgun proteomics, combined with enrichment analysis, jointly identified downregulated serum amyloid A1/A2 as an essential component underlying the combination treatment’s effectiveness. MASLD/MASH patient livers showed reduced PPARα and increased ERRα levels supporting disrupted NR crosstalk in the hepatocyte nucleus. Conclusion Our study comprehensively supports that dual nuclear receptor targeting by simultaneously increasing PPARα and diminishing ERRα activity may represent a viable novel strategy against MASLD. Lay summary Our study using three distinct MASLD mouse models shows that a simultaneous targeting of PPARα and ERRα reduces liver fat, fibrosis, inflammation, and tumor formation. The combination treatment modifies lipid metabolism pathways, and uniquely lowers levels of serum amyloid A1/A2 in the liver. Impact and implications Our research introduces a novel therapeutic strategy against MASLD by simultaneously increasing PPARα activity while diminishing ERRα activity. With PPARα agonists already tested in phase III clinical trials, ERRα ligands/modulators need further (clinical) development to make our findings applicable to both MASLD patients and physicians.

  • Bariatric surgery post-liver transplantation: A Belgian nationwide study

    by Louis Onghena, Anja Geerts, Frederik Berrevoet, Jacques Pirenne, Jef Verbeek, Eliano Bonaccorsi-Riani, Geraldine Dahlqvist, Luisa Vonghia, Olivier Detry, Jean Delwaide, et al.

    Weight gain poses a rising concern post-liver transplantation (LT), and metabolic dysfunction–associated steatotic liver disease might impair graft health. The timing is crucial when considering bariatric surgery (BS) in a population with liver disease or transplantation. BS can be considered for post-LT weight gain, although the evidence is limited and the long-term outcome still uncertain. We conducted a national retrospective analysis in 5 Belgian transplant centers and included 25 patients with an LT followed by a bariatric procedure. A total of 187 LT patients without BS were included for comparison. Clinical, biochemical, and outcome data were retrospectively retrieved. In our nationwide cohort, 25 patients had undergone BS post-LT, at a median 3.5 years after LT. Twenty-one (84.0%) patients received a sleeve gastrectomy (SG). Patients were predominantly male (72.0%), with a lower age at time of transplantation compared with the non-BS population (54.5 vs. 60.6, pppp=0.016). Notable reductions were observed in alanine transaminase levels (40.5±28.5 U/L to 27.1±25.1 U/L post-BS, p=0.05) and HbA1c levels (6.9±1.6 to 6.0±1.4 post-BS, p<0.001). Three patients were re-transplanted, and eight patients died, of which five (20.0%) due to a nonhepatic malignancy and one (4.0%) due to liver failure. SG is the favored BS post-LT and has proven to be safe and feasible in a post-LT setting with favorable metabolic consequences. SG post-LT is a valid treatment for de novo and recurrent metabolic dysfunction–associated steatotic liver disease post-LT. Although we report on the largest cohort to date, there is still a need for larger cohorts to examine the effect of BS on patient and graft survival.


  • Patients hospitalized with alcohol‐related liver disease and prior bariatric surgery are more prone to develop acute‐on‐chronic liver failure

    by Louis Onghena, Yves Van Nieuwenhove, Laurissa Demeulenaere, Lindsey Devisscher, Xavier Verhelst, Helena Degroote, Sarah Raevens, Hans Van Vlierberghe, Sander Lefere, Anja Geerts

    Background & Aims: Patients with a history of bariatric surgery (BS) are susceptible to developing alcohol use disorder. We and others have previously shown that these patients can develop severe alcohol‐related liver disease (ARLD). Our aim was to describe the demographics, co‐morbidities and mortality of a hospitalized population diagnosed with alcohol‐related liver disease, in relation to BS.Methods: We included 299 patients hospitalized with ARLD at the Ghent University Hospital between 1 January 2018 and 31 December 2022. Clinical, biochemical and outcome data were retrospectively retrieved from the most recent hospitalization. Statistical analysis was performed using the t test, Mann–Whitney U and χ2 tests.Results: Thirteen per cent (39/299) of patients admitted with ARLD had a history of bariatric surgery, of whom 25 (64.1%) had undergone Roux‐en‐Y gastric bypass. Patients with a history of BS were predominantly female (76.9%), in contrast to the non‐BS population (29.2%) (p < .0001), and despite being significantly younger (p < .0001) and had a similar survival (61.5% vs. 58.1%). Bariatric surgery and older age at diagnosis were both significantly associated with poorer transplant‐free survival. The cause of death was acute‐on‐chronic liver failure in 73.3% of BS patients, compared to only 19.2% of those without a history of BS (p < .0001). The weekly amount of alcohol consumed (p = .012) and duration of use (p < .0001) were significantly lower/shorter in the BS population.Conclusions: BS patients hospitalized with ARLD are predominantly younger women with a lower cumulative alcohol consumption compared to those without prior BS. BS impacted transplant‐free survival, with ACLF as the predominant cause of death in these patients.


  • Novel bariatric surgery models in mice-differential effects on body weight loss and fatty liver disease

    by Louis Onghena, Anneleen Heldens, Milton Antwi, Hans Van Vlierberghe, Xavier Verhelst, Lindsey Devisscher, Yves Van Nieuwenhove, Anja Geerts, Sander Lefere

  • The pan-PPAR agonist lanifibranor decreases portal pressure in models of both hepatic and prehepatic portal hypertension

    by Anneleen Heldens, Christophe Casteleyn, Louis Onghena, Milton Antwi, Benedicte Descamps, Christian Vanhove, Xavier Verhelst, Hans Van Vlierberghe, Lindsey Devisscher, Jean-Louis Junien, et al.

  • Peroxisome proliferator-activated receptor alpha and estrogen related receptor alpha ligand combinations ameliorate non-alcoholic fatty liver disease

    by Milton Antwi, Sander Lefere, Lisa Koorneef, Anneleen Heldens, Louis Onghena, Anja Geerts, Lindsey Devisscher, Karolien De Bosscher